Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 7/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122197 | 1.00 | CES2 (0.40) | CES2TSHRFAAHCES1GGPS1 | |
| SCHEMBL25122268 | 0.98 | CES2 (0.39) | CES2TSHRFAAHCES1GGPS1 | |
| SCHEMBL10577153 | 0.85 | CES2 (0.40) | CES2TSHRFAAHCES1GGPS1 | |
| SCHEMBL19133167 | 0.79 | CES2 (0.45) | CES2FAAHCES1GGPS1MEN1 | |
| SCHEMBL23987271 | 0.78 | CES2 (0.44) | CES2FAAHCES1GGPS1MEN1 | |
| SCHEMBL23987260 | 0.78 | CES2 (0.44) | CES2FAAHCES1GGPS1MEN1 | |
| SCHEMBL20067686 | 0.77 | GPR84 (0.54) | TSHRMEN1KMT2AHSD17B10 | |
| SCHEMBL3931271 | 0.77 | CES2 (0.40) | CES2GGPS1FDPS | |
| SCHEMBL220378 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL11292691 | 0.76 | TSHR (0.50) | CES2TSHRFAAHCES1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261455-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | SPECTRUM PHARMACEUTICALS, INC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261455-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | ERBB2, EGFR, ERBB3 | CES2 3793/4885TSHR 944/4885FAAH 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.